AN2 THERAPEUTICS INC (ANTX)

Company Profile

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The company is headquartered in Menlo Park, California and currently employs 35 full-time employees. The company went IPO on 2022-03-25. The firm is focused on developing treatments for rare, chronic and serious infectious diseases with high unmet needs. The Company’s initial product candidate is epetraborole, a once-daily, oral treatment for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic and progressive infectious disease caused by bacteria, mycobacteria. Epetraborole has antimycobacterial activity through the inhibition of an essential and universal step in bacterial protein synthesis. Its mechanism of action is enabled by boron chemistry, which is the Company’s core technology approach. Epetraborole is under development in a pivotal Phase II/III clinical trial as a once-daily, oral treatment for patients with NTM lung disease with an initial focus on treatment-refractory Mycobacterium avium complex (MAC) lung disease.

Company Info

AN2 THERAPEUTICS INC

1800 El Camino Real, Suite D

Menlo Park CALIFORNIA 90501

P: 16503319090

CEO: Robert Corrigan

Employees: 35

Website: https://www.an2therapeutics.com/